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To appraise improvement strategies adopted by low and middle income countries to 24 
increase access to cancer treatments and palliative care; and identify the facilitators 25 
and barriers to implementation. 26 
Methods 27 
A systematic review was conducted and reported in accordance with PRISMA 28 
statement. MEDLINE, CINAHL and the Cochrane Library databases were searched. 29 
Bias was assessed using the Standards for Quality Improvement Reporting 30 
Excellence, and evidence graded using the Australian National Health and Medical 31 
Research Council system. 32 
Results 33 
Of 3069 articles identified, 18 studies were included. These studies involved less than 34 
a tenth (n=12, 8.6%) of all low and middle income countries. Most were case reports 35 
(58%), and the majority focused on palliative care (n=11, 61%). Facilitators included: 36 
stakeholder engagement, financial support, supportive learning environment, and 37 
community networks. Barriers included: lack of human resources, financial 38 
constraints, and limited infrastructure. 39 
Conclusions 40 
There is limited evidence on sustainable strategies for increasing access to cancer 41 
treatments and palliative care in low and middle income countries. Future strategies 42 
should be externally evaluated and be tailored to address service delivery; workforce; 43 
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Many low and middle income countries (LMICs) are ravaged by significant 50 
socioeconomic and healthcare challenges, including a rapid escalation in non-51 
communicable diseases (NCDs), particularly cancer (Meara et al. 2015). Between 52 
1990 and 2013, the 70% increase in cancer mortality occurred in LMICs, with 196.3 53 
million disability-adjusted life years lost (Global Burden of Disease Cancer 54 
Collaboration et al. 2015). Globally, cancer incidence is projected to increase to 22.2 55 
million new cancer cases by 2030, and LMICs will bear the major burden (Bray et al. 56 
2012). 57 
To date, the focus has been on cancer prevention and screening strategies in LMICs 58 
(Hanson et al. 2015; Raesima et al. 2015). But to improve survival and quality of life, 59 
equitable access to cancer treatment and palliative care is imperative (Knaul et al. 60 
2011). However, many LMICs lack: national policies; infrastructure; skilled workforce; 61 
financial resources; technology; and information system  for quality cancer treatment 62 
and palliative care (Knaul et al. 2011; Ngwa and Ngoma 2016). Currently, 90% of 63 
cancer patients in low income countries are unable to access quality surgical care 64 
(Meara et al. 2015; Sullivan et al. 2015) and a third of LMICs have no functional 65 
radiotherapy services (Abdel-Wahab et al. 2017), while a fifth of those that do have 66 
only one radiotherapy machine per five million or more population (Abdel-Wahab et al. 67 
2017; Atun et al. 2015; Datta et al. 2014). In most LMICs, late-stage presentation is 68 
common and the only treatment option is palliative care (Knaul et al. 2011;  WHO 69 
2007). Yet, many LMICs are not able to provide the  52 cancer medicines and 22 pain 70 
and palliative care medicines on the World Health Organisation’s (WHO)  List of 71 
Essential Medicines (Vanderpuye et al. 2017; Wirtz et al. 2017). Consequently, 80% 72 




Given these challenges, innovative, cost-effective, and applicable improvement 74 
strategies are urgently needed. 75 
High income countries (HICs) able to develop, implement, sustain and scale-up 76 
strategies have made progress expanding access to cancer treatment and palliative 77 
care. Several systematic reviews focusing on access to cancer treatment and palliative 78 
care in HICs have documented:  i) facilitators such as: drive for quality clinical 79 
outcomes; strong political commitment; continuity of care; financial resources; 80 
educational opportunities; and patient need for care; and ii) barriers such as: lack of 81 
knowledge; lack of awareness and support; competing priorities; and pervasive 82 
misconceptions about treatment quality (Chamberlain et al. 2016; Luckett et al. 2013; 83 
Obeidat et al. 2011; Thompson et al. 2017). 84 
Understanding barriers and facilitators across policy, healthcare organisation and 85 
community are essential to inform access strategy implementation (WHO 2002a). Few 86 
systematic reviews in this area have focused on LMICs, which continue to hamper 87 
strategy implementation required to optimise cancer treatment and palliative care 88 
efforts. Accordingly, the aims of this systematic review were to: appraise improvement 89 
strategies adopted by LMICs to increase access to cancer treatment and palliative 90 
care; and identify the facilitators and barriers to implementation. 91 
Methods 92 
A systematic review conducted and reported in accordance with the Preferred 93 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement 94 




Eligibility criteria 96 
Included studies were: all conducted in countries categorised by the World Bank 97 
Group (2017) Classification as being ‘low income’, ‘middle income’, ‘developing’, ‘less 98 
resourced’ or ‘limited resourced’; published in an English peer-reviewed journal since 99 
1990; reporting empirical data related to the impact of a strategy, intervention or 100 
programme designed to improve access to cancer surgery, radiotherapy, cancer 101 
medicines and/or palliative care. An ‘access improvement strategy’ was defined as 102 
any programme, plan, intervention or policy implemented to ensure cancer surgery, 103 
radiotherapy, chemotherapy, other essential cancer medicines, and/or palliative care 104 
services were more available, accessible, adequate, affordable, and appropriate. 105 
Studies focusing exclusively on cancer prevention or early detection were excluded. 106 
Information sources and search strategy 107 
Search terms were devised from relevant Cochrane Reviews (Dudley and Garner 108 
2011; Kredo et al. 2013). A combination of Medical Subject Headings (MeSH) and 109 
keywords for LMICs, cancer, treatment modalities and healthcare delivery were used. 110 
Table ESM 1 in the Online Resource shows the detailed search strategy. 111 
Between 4th April and 6th May 2017, three electronic databases – MEDLINE (EBSCO), 112 
CINAHL (EBSCO) and the Cochrane Library, were searched for relevant articles. 113 
These were selected, as they provide indexing for extensive international journals and 114 
regularly updated with relevant resources covering health topics. Reference lists of 115 
relevant articles were hand searched to identify additional articles. Articles were 116 




Study selection 118 
After removal of duplicates, all titles and abstracts were screened against the eligibility 119 
criteria (AD). Ten percent of the articles were screened by a second reviewer (TL), 120 
with 98.5% agreement being reached. Ineligible articles were removed. Full-text of all 121 
potentially relevant articles were retrieved, and further eligibility and quality 122 
assessments were undertaken by AD alone, with discussions among the wider team 123 
as necessary. 124 
Data items and collection process 125 
Data were extracted into a standardised data collection form using Microsoft Excel 126 
2016 (AD) guided by a modified Standards for Quality Improvement Reporting 127 
Excellence (SQUIRE 2.0) tool (Ogrinc et al. 2016). 128 
Quality assessment 129 
The quality of the studies was also assessed based on SQUIRE (AD). The Australian 130 
National Health and Medical Research Council approved rating system was used to 131 
rank the level of evidence. 132 
Synthesis 133 
The multi-level WHO Innovative Care for Chronic Conditions (ICCC) framework was 134 
adopted as the analytical framework for this review (WHO 2002a). This framework 135 
details the essential building blocks for action at the: micro (patient and family), meso 136 
(healthcare organisation and community) and macro (positive policy environment) 137 
levels for developing, and re-designing healthcare systems globally (refer Fig. 1) 138 
(WHO 2002a). The ICCC framework also integrates the six building blocks identified 139 




service delivery; health workforce; information; medical products, vaccines and 141 
technologies; financing; and leadership and governance (stewardship) (WHO 2007). 142 
Due to the range of designs and outcomes involved, a narrative synthesis using 143 
approaches described by Popay and colleagues (2006) was adopted. Included studies 144 
were independently coded by two reviewers (AD and TL) to map strategies against 145 
the ICCC framework levels. Any discrepancies were resolved through discussion. 146 
Results 147 
The initial search identified 3063 articles, with another six identified during hand 148 
searching. After removal of duplicates and screening, 138 articles underwent a full-149 
text review. Nineteen articles met inclusion criteria, with one study reported across two 150 
publications (Garcia-Gonzalez et al. 2015; Kanavos et al. 2009) (refer Fig. 2). 151 
Study characteristics 152 
Evidence on strategies for increasing access to cancer treatments and palliative care 153 
came from 12 different LMICs, mostly African nations. Table ESM 2 in the Online 154 
Resource shows the strategies in the included studies. 155 
The majority of studies (61%, n=11) focused on increasing palliative care access (Ali 156 
2016; Banerjee 2009; Boit et al. 2014; Gafer and Elhaj 2014; Herce et al. 2014; 157 
Krakauer et al. 2015; Lal et al. 2015; Paiva et al. 2012; Shamieh and Hui 2015; 158 
Tapsfield and Bates 2011; Wang et al. 2013), while a fifth (22%, n=4) focused on 159 
strengthening radiotherapy services (Agrawal et al. 2011; Efstathiou et al. 2016; Einck 160 
et al. 2014; Galalae et al. 2015). A tenth (11% n=2) focused on improving integrative 161 
cancer care (Brown et al. 2017; Nwogu et al. 2016), and only one study focused on 162 




Quality assessment 164 
Apart from one (Wang et al. 2013) randomised controlled trial (RCT), with high cross-165 
group contamination, the studies all generated low-level evidence predominately from 166 
case reports (n=11, 61%) (Agrawal et al. 2011; Ali 2016; Boit et al. 2014; Brown et al. 167 
2017; Efstathiou et al. 2016; Einck et al. 2014; Galalae et al. 2015; Garcia-Gonzalez 168 
et al. 2015; Krakauer et al. 2015; Nwogu et al. 2016; Shamieh and Hui 2015). Overall, 169 
the studies were of poor quality. None were underpinned by a conceptual framework 170 
or theory; two-thirds (67%, n=12) did not evaluate the strategy (Ali 2016; Banerjee 171 
2009; Boit et al. 2014; Brown et al. 2017; Efstathiou et al. 2016; Einck et al. 2014; 172 
Gafer and Elhaj 2014; Garcia-Gonzalez et al. 2015; Krakauer et al. 2015; Nwogu et 173 
al. 2016; Shamieh and Hui 2015; Tapsfield and Bates 2011); 44% (n=8) did not 174 
describe the methods (Boit et al. 2014; Efstathiou et al. 2016; Einck et al. 2014; Gafer 175 
and Elhaj 2014; Galalae et al. 2015; Garcia-Gonzalez et al. 2015; Krakauer et al. 2015; 176 
Shamieh and Hui 2015); and less than a third (n=5) had secured ethics approval 177 
(Galalae et al. 2015; Herce et al. 2014; Paiva et al. 2012; Tapsfield and Bates 2011; 178 
Wang et al. 2013). 179 
Positive policy environment facilitators and barriers 180 
Seven main positive policy environment facilitators emerged as being crucial to the 181 
successful implementation of the access improvement strategies (refer Table 1). 182 
Stakeholder engagement (Agrawal et al. 2011; Ali 2016; Banerjee 2009; Boit et al. 183 
2014; Brown et al. 2017; Efstathiou et al. 2016; Einck et al. 2014; Gafer and Elhaj 184 
2014; Galalae et al. 2015; Garcia-Gonzalez et al. 2015; Herce et al. 2014; Kanavos et 185 
al. 2009; Krakauer et al. 2015; Nwogu et al. 2016; Tapsfield and Bates 2011) and 186 
financial support (Agrawal et al. 2011; Ali 2016; Boit et al. 2014; Brown et al. 2017; 187 




al. 2014; Kanavos et al. 2009; Nwogu et al. 2016; Tapsfield and Bates 2011) were 189 
identified as critical facilitators across all access improvement strategies 190 
implementation. Embedding a shared understanding of the project importance and the 191 
proposed action(s) and facilitating a sense of co-creation and ownership, were the key 192 
primary focus of the stakeholder engagement strategies implemented across the 193 
projects. Through the co-creation of a cancer centre, there was an estimated 17% 194 
average annual increase in cancer patients accessing care which was observed 195 
between 2014-2016 (Nwogu et al. 2016). 196 
Five key positive policy environment barriers that impeded the implementation of the 197 
planned access improvement strategies were identified. Across four studies, lack of 198 
human resources was the most critical barrier to the implementation of access 199 
improvement strategies (Brown et al. 2017; Efstathiou et al. 2016; Einck et al. 2014; 200 
Gafer and Elhaj 2014). Several studies acknowledged financial constraints and lack 201 
of political commitment as major barriers to implementation (Ali 2016; Nwogu et al. 202 
2016). Collectively these identified barriers contributed to: strategy implementation 203 
delays (Ali 2016; Gafer and Elhaj 2014); high health professionals workloads 204 
(Efstathiou et al. 2016; Einck et al. 2014); and patients experiencing long waiting times 205 
to be seen by health professionals (Brown et al. 2017; Nwogu et al. 2016). 206 
Healthcare organisation facilitators and barriers 207 
Of the eight healthcare organisation facilitators identified, creating a supportive 208 
learning environment was key to increasing integrated cancer care, radiotherapy, 209 
and/or palliative care access. Thirteen studies with varying levels of evidence reported 210 
creating a supportive learning environment for health professionals to develop 211 




2009; Boit et al. 2014; Brown et al. 2017; Gafer and Elhaj 2014; Herce et al. 2014; 213 
Krakauer et al. 2015; Lal et al. 2015; Nwogu et al. 2016; Paiva et al. 2012; Shamieh 214 
and Hui 2015; Tapsfield and Bates 2011). The RCT reported a significant increase in 215 
patients’ knowledge of cancer pain and pain control by employing task-shifting strategy 216 
(p<0.05) (Wang et al. 2013). Few studies targeted financial hardship and treatment 217 
adherence by offering free access to essential cancer and palliative care medicines 218 
(Garcia-Gonzalez et al. 2015; Kanavos et al. 2009; Lal et al. 2015). While a significant 219 
increase in survival could not be determined in a retrospective review of the outcome 220 
of the free drug donation strategy, a three-year survival rate of 66% was reported 221 
among 13,568 patients (Kanavos et al. 2009). Access improvement strategies tailored 222 
to local resources and conditions generated better acceptance of the changes (Einck 223 
et al. 2014; Galalae et al. 2015; Garcia-Gonzalez et al. 2015). 224 
Ten healthcare organisation barriers to access improvement strategies 225 
implementation were identified, with the majority related to radiotherapy access, such 226 
as: limited physical infrastructure (Efstathiou et al. 2016; Einck et al. 2014); lack of 227 
radiotherapy equipment (Efstathiou et al. 2016; Einck et al. 2014); and radiotherapy 228 
equipment maintenance difficulties (Efstathiou et al. 2016). Untimely delivery of 229 
appropriate radiotherapy doses was a major negative consequence. The most 230 
challenging aspect of chemotherapy access improvement strategies were: poor 231 
internet connectivity, identifying and verifying eligible cancer patients, as well as 232 
maintaining communication between strategy providers and health professionals 233 
(Garcia-Gonzalez et al. 2015; Kanavos et al. 2009). While a small number of studies 234 
suggested that prohibitive cancer treatment cost limited access for cancer patients and 235 
their families (Einck et al. 2014; Nwogu et al. 2016), no economic evidence estimating 236 




Community facilitators and barriers 238 
Two community facilitators that supported the successful implementation of integrative 239 
cancer care and palliative care access improvement strategies were identified (Boit et 240 
al. 2014; Herce et al. 2014; Nwogu et al. 2016). Across two studies, community 241 
networks were important providers of complementary services, such as 242 
socioeconomic supports (Boit et al. 2014; Herce et al. 2014). A critical facilitator was 243 
mobilising and coordinating community resources. One study acknowledged that 244 
establishing a non-governmental organisation (NGOs) offered unique opportunities to 245 
mobilised funds and coordinated with other community institutions to foster greater 246 
community buy-in of improvement strategies (Nwogu et al. 2016). 247 
Culturally-related beliefs, attitudes and practices toward cancer and treatment 248 
modalities, was the only community level barrier identified which adversely impacted 249 
on communities or individuals’ non-acceptance of the radiotherapy and palliative care 250 
access improvement strategies on offer (Efstathiou et al. 2016; Gafer and Elhaj 2014). 251 
Discussion 252 
Unfortunately, there is no high-level evidence to recommend any particular strategy to 253 
increase access to cancer treatments or palliative care in LMICs. Most strategies have 254 
focused on increasing palliative care, and none on increasing access to surgical care, 255 
the mainstay of curative cancer care (Sullivan et al. 2015). 256 
No strategies to date have been robustly evaluated or have included a health 257 
economic evaluation. None have made use of an implementation framework. 258 
However, despite limitations in the quality of the studies, the literature yields valuable 259 




The included studies revealed numerous facilitators and barriers affecting the 261 
successful implementation of access improvement strategies at all three levels of the 262 
ICCC framework. These facilitators and barriers were complex and overlapping, 263 
concerned with: stakeholder engagement, financial support, supportive learning 264 
environment, strong community networks, lack of human resources, financial 265 
constraints, and limited infrastructure. These results confirm the complexity of 266 
implementing healthcare change, which requires an understanding of: processes of 267 
implementation; factors affecting implementation; the introduction of solutions, scale-268 
up, and longer-term sustainability (Nilsen 2015; Peters et al. 2013). 269 
Financing, partnership, legislative frameworks, policy integration, leadership and 270 
advocacy, development and allocation of human resources are key requirements of a 271 
positive policy environment (WHO 2002a). This review has highlighted the importance 272 
of acquiring the necessary financial support before embarking on any access 273 
improvement strategy. Financing of access improvement strategies determines who 274 
provides funds, and who exercises influence over the funds. International donors 275 
increasing their financing priority have been the key driving force for strengthening 276 
palliative care services in LMICs (Ali 2016; Boit et al. 2014; Gafer and Elhaj 2014; 277 
Herce et al. 2014; Tapsfield and Bates 2011), while locally based NGOs ability to 278 
established international ties is central to mobilising international funds for other 279 
cancer treatment initiatives (Nwogu et al. 2016). Donor funding approach for a specific 280 
purpose restricts strategy scope and limits the sponsors ability to address unique local 281 
needs. This mismatch contributes to poor strategy acceptance at the local level. 282 
The private sector’s financial participation in the health sector in most LMICs has 283 
contributed significantly to the availability of radiotherapy (Efstathiou et al. 2016), 284 




cancer care (Nwogu et al. 2016). However, private sector financing approach in LMICs 286 
exposes’ patients without private health insurance and their families, who make up 287 
most of these populations, to extreme financial hardships making it impossible for 288 
them to pay or adhere to care. As universal health coverage is yet to be fully realised 289 
in most LMICs (WHO and World Bank 2015), medical expenses related to cancer 290 
treatments continue to serve as a barrier to the successful improvement strategies 291 
implementation (Einck et al. 2014; Nwogu et al. 2016). There is an urgent need to 292 
institutionalise an appropriate financing system at the national level that offers the right 293 
financial incentives for providers, and protects cancer patients from financial hardships 294 
(WHO 2007). 295 
Policies at the international, national, and regional levels are major issues in the 296 
successful implementation of access improvement strategies. This review identified a 297 
paucity of evidence about policy development and implementation to improve access 298 
to cancer treatments and palliative care. Recently, WHO (2002a; 2002b) has assumed 299 
a more central position in providing supports for policy development process in most 300 
LMICs, which is crucial to driving in-country reform. A cancer policy  framework helps 301 
guide  critical decisions and systematic course of actions by governments and other 302 
stakeholders, both of which are essential to improving cancer control (Adshead and 303 
Thorpe 2008). In LMICs, there remains a significant need for: credible policy agenda 304 
setting, realistic policy formulation; timely policy implementation; and periodic policy 305 
monitoring and evaluation using a theoretical framework (Exworthy 2008). Successful 306 
design and implementation of LMIC cancer control policies requires high quality health 307 
services research evidence, long-term commitment of resources, institutional capacity 308 
to enhance sustainability and reach of the policy, and co-designed approaches. While 309 




policy-makers and supporting partners should consider the context, and power to 311 
obtain a full understanding of local policy process (Exworthy 2008). 312 
Our findings are consistent with other literature on the need to gain commitment and 313 
buy-in from key stakeholders, especially those in positions of authority (Ramaswamy 314 
and Gouillart 2010). Meaningful engagement of key stakeholders plays an essential 315 
role in achieving commitment at the political and community levels. Participatory and 316 
co-design driven approach to implementation will assist in structuring health services 317 
to deliver effective, safe, and quality cancer treatments and palliative care. 318 
Participatory approach offers stakeholders: a more active and significant role in 319 
defining their priorities; diagnosing their challenges; securing funds; and implementing 320 
appropriate solutions for service improvement (Bate and Robert 2006). 321 
The ICCC framework employs a population health approach including: promoting 322 
continuity and coordination, encouraging quality through leadership and incentives, 323 
organising and equipping healthcare teams, using information systems, and 324 
supporting self-management and prevention (WHO 2002a). The performance of the 325 
health workforce drives health system improvement strategies and determines how 326 
care is delivered. Developing and strengthening a country-based and country-led 327 
health workforce education initiative with appropriate international support is essential 328 
(Chen et al. 2004) if a responsive, fair, and efficient health outcome is to be realised. 329 
A country-based educational strategy helps reduce the outward migration of skilled 330 
health professionals from LMICs to HICs. An essential step towards achieving 331 
universal access to quality cancer treatments and palliative care is shifting human 332 
resource responsibilities and providing generalist doctors, nurses, allied health 333 




training, assessment tools, and essential medicines to deliver appropriate hospital and 335 
home-based care (Knaul et al. 2017; Knaul et al. 2011). 336 
Implementation was largely affected by essential equipment challenges, particularly 337 
radiotherapy. Essential medical equipment, such as linear accelerators and high-338 
dose-rate brachytherapy, are of paramount importance in cancer treatments and 339 
palliative care. Access to essential medical equipment provides the required 340 
assurance of quality, safety, efficacy, cost-effective, and scientific care delivery (WHO 341 
2007). However, most LMICs: lack essential radiotherapy equipment; are faced with 342 
periodic radiotherapy equipment breakdowns; or have poor radiotherapy equipment 343 
maintenance culture. Given that radiotherapy equipment is expensive to install, it is 344 
imperative to develop and implement specific preventive and corrective maintenance 345 
schedules, procedures and tasks to reduce unnecessary operational interruptions due 346 
to breakdowns. These challenges are part of a broader medical equipment problems 347 
in most LMICs. Hence, to improve access to essential medical equipment, there is a 348 
need to develop simple, quality, and affordable medical technologies. By designing 349 
and engineering tools, and techniques less than 500 nanometers in size, emerging 350 
field of nanotechnology offers significant opportunity in overcoming different barriers 351 
to cancer treatments (Cuenca et al. 2006). Such technologies can help reduce the 352 
size, weight, shielding, and shipping costs of medical equipment. Moreover, the 353 
technological advances can lead to a reduction of power consumption necessary for 354 
operating the equipment, and limited heat production. There should be greater 355 
emphasis on developing solar-powered equipment with high-quality insulation to limit 356 
the dependence on national power grid (Atun et al. 2015). 357 
The ICCC framework assigns significant emphasis to the community, acknowledging 358 




prepared community resources help to promote awareness and reduce stigma, 360 
provide leadership and support, and deliver complementary services to ensure better 361 
outcomes for chronic care conditions (WHO 2002a). Recognising that community 362 
agencies, organisations, institutions, opinion leaders, and concern citizens are major 363 
stakeholders in strengthening cancer treatments and palliative care delivery will 364 
require promoting acceptance and understanding of the notion of community 365 
involvement in health and development (Kahssay and Oakley 1999). The community 366 
development literature may prove useful in designing and implementing access 367 
improvement strategies. By definition, community development contributes to 368 
resource mobilisation, local empowerment, capacity development, and growth of 369 
political action through a network of relationships to help include the perspective and 370 
experience of grassroots (Helling et al. 2005). 371 
Identified gaps 372 
Investing and expanding surgical and radiotherapy capacity ought to be an important 373 
priority for all LMICs. Well-established knowledge of the minimum standards for quality 374 
cancer surgery and radiotherapy already exist  and include: establishing or adopting 375 
national accreditation systems; scaling up surgical and radiotherapy workforce; 376 
providing competency license; and aligning surgical and radiotherapy access with 377 
universal health coverage (Atun et al. 2015; Meara et al. 2015; Sullivan et al. 2015). 378 
Another gap relates to the lack of incentives and rewards available for health 379 
professionals in LMICs. Incentives and rewards systems should be created for 380 
motivating health professionals. Both financial and non-financial incentives are 381 
essential to encourage health professionals to effectively perform, and engage in 382 




While there is an urgent need to increase the access to best evidence-based cancer 384 
care for people living in LMICs, this review highlights the importance of access to: 385 
universal health insurance, so that more people who need cancer care can afford to 386 
access the care they need; and essential cancer and palliative care medications, as 387 
per the WHO lists. 388 
Future directions 389 
There are opportunities to draw valuable lessons from the experience in developing 390 
and implementing HIV/AIDS strategies in LMICs, as well as cancer treatment and 391 
palliative care strategies in HICs. Key among these lessons are: global mobilisation 392 
and investment funds; engagement of pharmaceutical companies; development of 393 
simply health technologies; strengthening health workforce capacity; development of 394 
a supportive national policy framework; connecting health system with community 395 
resources; and community participatory in strategy development (Khumalo-396 
Sakutukwa et al. 2008; Knaul et al. 2011; Muthee et al. 2018; Narayan et al. 2011). 397 
Recognising the importance of national policies in cancer control; dedicated financial 398 
budgets supporting cancer control; high level of advocacy and community involvement 399 
in strategy design; strong political support and acceptability of cancer control 400 
strategies; progress in cutting-edge technological advancements; and promoting high 401 
quality cancer research and evidence-based treatment, are critical to taking cancer 402 
care in LMICs to the next stage of their development (Knaul et al. 2011; Obeidat et al. 403 
2011; Thompson et al. 2017). 404 
Applying existing implementation research theories to future strategies designs will 405 
assist in strengthening the work undertaken to improve access to cancer treatments 406 




access improvement strategies as an essential precursor to an effective adoption is 408 
an important next step. A readiness assessment provides strategy implementers with 409 
a preliminary understanding of the barriers and facilitators they are likely to encounter 410 
when implementing improvement strategies (Helfrich et al. 2009). To help prioritise 411 
actions and mitigate implementation barriers, increased focus on readiness are 412 
needed so that evidence base for LMICs capacity, preparedness, commitment and 413 
willingness to support cancer treatment and palliative care strategy implementation, 414 
sustainability and scale-up is available to assist policy-makers. Such focus is of 415 
particularly importance to expanding access to cancer treatment and palliative care in 416 
LMICs. 417 
Strengths and limitations 418 
The systematic search of articles and application of an internationally recognised 419 
framework are strengths of this review. While this review distilled various facilitators 420 
and barriers to the successful implementation from the studies, these were not 421 
systematically or explicitly investigated using primary research techniques. The results 422 
should be interpreted with caution because the studies included were low-level 423 
evidence, at the descriptive level except for one randomised control trial (Wang et al. 424 
2013). None of the studies referenced the ICCC framework, which may not be an ideal 425 
‘fit’ for some countries’ health systems. 426 
Conclusions 427 
While modest progress has been made to increase access to cancer treatments and 428 
palliative care in LMICs, some major gaps still exist. In taking this work forward, LMICs 429 
are advised to adopt internationally recognised frameworks, such as the ICCC or the 430 




outcomes to assist leaders to assess local population needs and integrate initiatives 432 
systematically, engage with the appropriate stakeholders and secure the necessary 433 
financial support. It is essential to include an evaluation plan and budget during the 434 
development of the access improvement strategy. Needs assessment and design 435 
evaluation should be undertaken by an independent evaluator to ensure that a reliable 436 
blind outcome-based analysis is generated. 437 
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Table 1 Summary of the facilitators and barriers to implementation of cancer treatment and palliative care strategies in low and middle 646 
income countries, 1990-2017 647 
ICCC levels Facilitators Barriers 
 Positive Policy 
Environment 
Prepared health professionals (Ali 2016; Banerjee 2009; Boit et al. 2014; Brown et al. 2017; Gafer 
and Elhaj 2014; Herce et al. 2014; Krakauer et al. 2015; Nwogu et al. 2016; Paiva et al. 2012; 
Shamieh and Hui 2015; Tapsfield and Bates 2011) 
Lack of human resources (Brown et al. 2017; 
Efstathiou et al. 2016; Einck et al. 2014; Gafer and 
Elhaj 2014) 
  Financial support (Agrawal et al. 2011; Ali 2016; Boit et al. 2014; Brown et al. 2017; Efstathiou et 
al. 2016; Gafer and Elhaj 2014; Garcia-Gonzalez et al. 2015; Herce et al. 2014; Kanavos et al. 
2009; Nwogu et al. 2016; Tapsfield and Bates 2011) 
 
Financial constraints (Ali 2016; Nwogu et al. 2016) 
  Political commitment (Agrawal et al. 2011; Ali 2016; Brown et al. 2017; Efstathiou et al. 2016; Herce 
et al. 2014; Krakauer et al. 2015) 
Limited political commitment (Ali 2016; Nwogu et al. 
2016) 
 Stakeholder engagement (Brown et al. 2017; Nwogu et al. 2016) (Agrawal et al. 2011; Ali 2016; 
Banerjee 2009; Boit et al. 2014; Efstathiou et al. 2016; Einck et al. 2014; Gafer and Elhaj 2014; 
Galalae et al. 2015; Garcia-Gonzalez et al. 2015; Herce et al. 2014; Kanavos et al. 2009; Krakauer 
et al. 2015; Tapsfield and Bates 2011) 
 
Restrictive pharmacovigilance laws and 
regulations (Garcia-Gonzalez et al. 2015; Kanavos 
et al. 2009) 
  Positive relationships with international organisations (Ali 2016; Brown et al. 2017; Efstathiou et al. 
2016; Einck et al. 2014; Gafer and Elhaj 2014; Galalae et al. 2015; Krakauer et al. 2015; Nwogu et 
al. 2016) 
Drug importation process challenges (Garcia-
Gonzalez et al. 2015; Kanavos et al. 2009) 
  Committed champions (Ali 2016; Banerjee 2009; Boit et al. 2014; Gafer and Elhaj 2014; Herce et 
al. 2014; Krakauer et al. 2015; Nwogu et al. 2016) 
 
  Strategy aligned with national policy(Efstathiou et al. 2016)   
 Healthcare 
Organisation 
Supportive learning environment (Agrawal et al. 2011; Ali 2016; Banerjee 2009; Boit et al. 2014; 
Brown et al. 2017; Gafer and Elhaj 2014; Herce et al. 2014; Krakauer et al. 2015; Lal et al. 2015; 
Nwogu et al. 2016; Paiva et al. 2012; Shamieh and Hui 2015; Tapsfield and Bates 2011) 
Limited physical infrastructure (Banerjee 2009; 
Efstathiou et al. 2016; Einck et al. 2014; Gafer and 
Elhaj 2014) 
 Recognition of patients’ needs (Banerjee 2009; Brown et al. 2017; Gafer and Elhaj 2014; Garcia-
Gonzalez et al. 2015; Herce et al. 2014; Kanavos et al. 2009; Lal et al. 2015; Nwogu et al. 2016; 
Paiva et al. 2012; Shamieh and Hui 2015; Wang et al. 2013) 
Prohibitive treatment costs (Einck et al. 2014; Nwogu 
et al. 2016) 
  Patient symptom management education (Banerjee 2009; Gafer and Elhaj 2014; Herce et al. 2014; 
Lal et al. 2015; Paiva et al. 2012; Shamieh and Hui 2015; Wang et al. 2013) 
Lack of WHO essential pain and palliative care 




ICCC levels Facilitators Barriers 
  Strategy coordinator (Herce et al. 2014; Shamieh and Hui 2015; Tapsfield and Bates 2011) Fragmented health system (Efstathiou et al. 2016) 
  Adherence to evidence-based practice (Einck et al. 2014; Galalae et al. 2015) Irregular meeting attendance (Agrawal et al. 2011; 
Brown et al. 2017) 
  Strategy tailored to local resources and conditions (Einck et al. 2014; Galalae et al. 2015; Garcia-
Gonzalez et al. 2015; Kanavos et al. 2009) 
Limited or lack of radiotherapy equipment (Brown et 
al. 2017; Efstathiou et al. 2016; Einck et al. 2014; 
Nwogu et al. 2016) 
  Information management system (Brown et al. 2017; Nwogu et al. 2016) Poor internet connectivity (Agrawal et al. 2011) 
(Garcia-Gonzalez et al. 2015; Kanavos et al. 2009) 
 Clearly defined strategy objectives (Agrawal et al. 2011; Brown et al. 2017; Galalae et al. 2015) Radiotherapy equipment maintenance 
difficulties (Efstathiou et al. 2016) 
  Periodic radiotherapy equipment 
breakdown (Efstathiou et al. 2016) 
  Unstable electricity supply (Efstathiou et al. 2016) 
Community Strong community networks (Boit et al. 2014; Herce et al. 2014) Culturally-related beliefs, attitudes and practices 
towards cancer and treatment modalities  (Efstathiou 
et al. 2016; Gafer and Elhaj 2014) 
  Mobilisation and coordination of resources (Nwogu et al. 2016)  
Explanation of abbreviations: ICCC = Innovative Care for Chronic Conditions 648 
 649 
 650 
